4/A: Brainstorm Cell Therapeutics CEO Corrects Transaction Codes in Amended SEC Filing

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous Form 4 to correct transaction codes related to common stock purchases.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, filed an amended Form 4 with the SEC on July 31, 2024.
• This amendment corrects an administrative error in the original Form 4 filed on May 14, 2024, which incorrectly used transaction code 'A' instead of the correct code 'P'.
• The corrected filing reflects purchases of Brainstorm Cell Therapeutics common stock by Lebovits on May 10, 2024 (20,000 shares at $0.465), May 11, 2024 (10,000 shares at $0.4665), and May 13, 2024 (10,000 shares at $0.49).
• Following these transactions, Lebovits directly owns 1,099,865 shares of common stock.
• He may also be deemed the beneficial owner of 2,000,847 indirectly held shares, including 1,933,794 shares owned by ACCBT Corp. and 67,053 shares owned by ACC International Holdings Ltd.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to insider trading activity, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Key Dates

Keywords

Form 4, amendment, Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, common stock, SEC filing, transaction code, beneficial ownership